BioNTech’s Founders Launch a Biotech Spin-Out as the Market Waits for Q2 Clarity
Published on 07/27/2026 at 08:51 | Redaktion boerse-global.de
The next few weeks could define the narrative for BioNTech for the rest of 2026. With the company’s second-quarter earnings scheduled for August 4, investors are grappling with two competing visions: one built on a shrinking pandemic-era revenue stream, the other on a high-stakes pivot to oncology that has yet to deliver a commercial payoff.
But a new layer of strategic complexity has emerged. Co-founders Ugur Sahin and Ă–zlem TĂĽreci are pushing ahead with plans to establish a separate biotechnology company focused exclusively on mRNA foundational research. BioNTech intends to contribute certain mRNA technologies and rights to the new entity in exchange for a minority stake. The move, first announced earlier this year, is designed to let the parent company concentrate fully on its late-stage pipeline while retaining a scientific link to its mRNA roots. Investors are still waiting for the binding contracts, which were originally expected by mid-2026.
At the heart of BioNTech’s commercial future is Pumitamig, or BNT327, a bispecific antibody targeting PD-L1 and VEGF-A that is being developed in partnership with Bristol Myers Squibb. The drug candidate is currently running in five potentially registration-enabling studies, including the global ROSETTA-Lung-02 trial for non-small cell lung cancer and a study in triple-negative breast cancer. The company’s broader ambition is to have 15 active Phase 3 oncology trials underway by the end of the year. Outside oncology, the mRNA-based HIV vaccine candidate BNT168 is expected to advance in clinical testing this month.
Should investors sell immediately? Or is it worth buying BioNTech?
The stock closed the past trading week at €78.75, down 2.66% on Friday. That leaves it 25.57% below its 52-week high of €105.80, reached in late January. Technically, the shares are trading just under the 50-day moving average of €79.39 and well below the 200-day line of €84.63. The relative strength index sits at 43.2, suggesting a neutral-to-slightly-bearish bias rather than an oversold condition.
BioNTech’s financial position remains a powerful buffer against market skepticism. At the end of the first quarter, the company held roughly €16.8 billion in cash, liquid assets, and securities. With a market capitalization of just under €19.8 billion, the equity value is barely above the cash pile itself. That dynamic has fueled debate between two camps: growth-oriented analysts who see the oncology pipeline as a catalyst between 2026 and 2030, and value-focused investors who question whether years of heavy R&D spending will translate into marketable products.
The average analyst rating is still a “Moderate Buy,” with price targets above €120. But the chart suggests a market in wait-and-see mode. In the week starting July 27, attention is likely to focus on the support zone near €78, with trading driven more by positioning ahead of the earnings date than by any near-term clinical catalysts.
The August 4 report is expected to provide clarity on capital allocation and deliver concrete timelines for several late-stage study readouts. Data on Pumitamig and the antibody Gotistobart will be closely watched for signs that clinical progress can justify a post-pandemic valuation reset. Until then, the market remains caught between a shrinking legacy business and a pipeline that has yet to prove its commercial weight.
Ad
BioNTech Stock: New Analysis - 27 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
